Get started
Fate Therapeutics, Inc.Fate Therapeutics, Inc.Fate Therapeutics, Inc.

Fate Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

FATE chart


Full chart

FATE upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪151.48 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.65 USD
Net income (FY)
‪−160.93 M‬ USD
Revenue (FY)
‪63.53 M‬ USD
Shares float
‪97.84 M‬
Beta (1Y)
1.97

Employees


Employees (FY)
181
Change (1Y)
−370 −67.15%
Revenue / Employee (1Y)
‪351.01 K‬ USD
Net income / Employee (1Y)
‪−889.10 K‬ USD

About Fate Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Bahram Valamehr
Website
fatetherapeutics.com
Headquarters
San Diego
Founded
2007
FIGI
BBG000QP35H2
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

FATE news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of FATE is 1.33 USD — it has decreased by −0.75% in the past 24 hours. Watch Fate Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Fate Therapeutics, Inc. stocks are traded under the ticker FATE.
FATE stock has risen by 3.91% compared to the previous week, the month change is a −19.88% fall, over the last year Fate Therapeutics, Inc. has showed a −71.46% decrease.
We've gathered analysts' opinions on Fate Therapeutics, Inc. future price: according to them, FATE price has a max estimate of 10.00 USD and a min estimate of 3.00 USD. Watch FATE chart and read a more detailed Fate Therapeutics, Inc. stock forecast: see what analysts think of Fate Therapeutics, Inc. and suggest that you do with its stocks.
FATE reached its all-time high on Jan 14, 2021 with the price of 121.16 USD, and its all-time low was 1.04 USD and was reached on Jan 14, 2025. View more price dynamics on FATE chart.
See other stocks reaching their highest and lowest prices.
FATE stock is 4.65% volatile and has beta coefficient of 1.97. Track Fate Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Fate Therapeutics, Inc. there?
Today Fate Therapeutics, Inc. has the market capitalization of ‪151.48 M‬, it has decreased by −26.29% over the last week.
Yes, you can track Fate Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Fate Therapeutics, Inc. is going to release the next earnings report on Mar 3, 2025. Keep track of upcoming events with our Earnings Calendar.
FATE earnings for the last quarter are −0.40 USD per share, whereas the estimation was −0.42 USD resulting in a 3.95% surprise. The estimated earnings for the next quarter are −0.44 USD per share. See more details about Fate Therapeutics, Inc. earnings.
Fate Therapeutics, Inc. revenue for the last quarter amounts to ‪3.07 M‬ USD, despite the estimated figure of ‪1.24 M‬ USD. In the next quarter, revenue is expected to reach ‪1.62 M‬ USD.
FATE net income for the last quarter is ‪−47.68 M‬ USD, while the quarter before that showed ‪−38.43 M‬ USD of net income which accounts for −24.07% change. Track more Fate Therapeutics, Inc. financial stats to get the full picture.
No, FATE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jan 27, 2025, the company has 181.00 employees. See our rating of the largest employees — is Fate Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Fate Therapeutics, Inc. EBITDA is ‪−177.57 M‬ USD, and current EBITDA margin is −250.78%. See more stats in Fate Therapeutics, Inc. financial statements.
Like other stocks, FATE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Fate Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Fate Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Fate Therapeutics, Inc. stock shows the sell signal. See more of Fate Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.